Bio‐adrenomedullin as a marker of congestion in patients with new‐onset and worsening heart failure. (6th March 2019)

• Record Type: Journal Article
• Authors: ter Maaten, Jozine M.; Kremer, Daan; Demissei, Biniyam G.; Struck, Joachim; Bergmann, Andreas; Anker, Stefan D.; Ng, Leong L.; Dickstein, Kenneth; Metra, Marco; Samani, Nilesh J.; Romaine, Simon P.R.; Cleland, John; Girerd, Nicolas; Lang, Chim C.; van Veldhuisen, Dirk J.; Voors, Adriaan A.
• Is Part Of: European journal of heart failure. Volume 21:Number 6(2019)
• Page Start: 732
• Page End: 743
• Publication Date: 2019-03-06
• Subjects: Bio‐adrenomedullin -- Pro‐adrenomedullin -- Adrenomedullin -- Heart failure -- Congestion; Heart failure -- Periodicals; Heart Failure -- Periodicals; Insuffisance cardiaque -- Périodiques; Heart failure; Periodicals; 616.129005
• DOI: 10.1002/ejhf.1437
• Languages: English
• ISSNs: 1388-9842

Abstract

Abstract : Background: Secretion of adrenomedullin (ADM) is stimulated by volume overload to maintain endothelial barrier function, and higher levels of biologically active (bio‐) ADM in heart failure (HF) are a counteracting response to vascular leakage and tissue oedema. This study aimed to establish the value of plasma bio‐ADM as a marker of congestion in patients with worsening HF. Methods and results: The association of plasma bio‐ADM with clinical markers of congestion, as well as its prognostic value was studied in 2179 patients with new‐onset or worsening HF enrolled in BIOSTAT‐CHF. Data were validated in a separate cohort of 1703 patients. Patients with higher plasma bio‐ADM levels were older, had more severe HF and more signs and symptoms of congestion (all P < 0.001). Amongst 20 biomarkers, bio‐ADM was the strongest predictor of a clinical congestion score ( r 2 = 0.198). In multivariable regression analysis, higher bio‐ADM was associated with higher body mass index, more oedema, and higher fibroblast growth factor 23. In hierarchical cluster analysis, bio‐ADM clustered with oedema, orthopnoea, rales, hepatomegaly and jugular venous pressure. Higher bio‐ADM was independently associated with impaired up‐titration of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers after 3 months, but not of beta‐blockers. Higher bio‐ADM levels were independently associated with an increased risk of all‐cause mortality and HF hospitalization (hazard ratio 1.16, 95% confidence interval 1.06–1.27, P = 0.002, per log increase). Analyses in the validation cohort yielded comparable findings. Conclusions: Plasma bio‐ADM in patients with new‐onset and worsening HF is associated with more severe HF and more oedema, orthopnoea, hepatomegaly and jugular venous pressure. We therefore postulate bio‐ADM as a congestion marker, which might become useful to guide decongestive therapy.